| Literature DB >> 34081314 |
Barbara H Rosario1, Humaira Shafi2, Anthony C A Yii3, Louis Y Tee4, Arron S H Ang5, Gek Kheng Png4, Wendy S T Ang4, Yan Qing Lee4, Pei Ting Tan6, Aniruddha Sahu4, Lin Fang Zhou4, Yi Ling Zheng4, Roslinda Binte Slamat4, Aza A M Taha3.
Abstract
AIMS: To evaluate the efficacy of multi-component interventions for prevention of hospital-acquired pneumonia in older patients hospitalized in geriatric wards.Entities:
Keywords: Multi-component interventions; Nosocomial infection; Older adults; Pneumonia; Randomized controlled trial
Mesh:
Year: 2021 PMID: 34081314 PMCID: PMC8173511 DOI: 10.1007/s41999-021-00506-3
Source DB: PubMed Journal: Eur Geriatr Med ISSN: 1878-7649 Impact factor: 1.710
Fig. 1Reverse Trendelenburg position or whole bed tilt
Fig. 4Dysphagia screen undertaken by Research Team Members
(adapted from the Toronto Bedside Swallowing Screening Test (TOR-BSST) (Martino et al., 2008))
Fig. 2Flow chart showing enrolment, randomization, allocation, follow-up and analysis phases
Baseline characteristics of study participants
| All | Usual care (control) | Intervention | ||
|---|---|---|---|---|
| Number of participants | 123 | 64 | 59 | |
| Age, median (years) | 85 | 88 | 84 | 0.13 |
| Interquartile range | (81–88) | (82–89) | (81–88) | |
| Min–max | 71–101 | 71–97 | 71–101 | |
| Male | 53 (43.1%) | 24 (37.5%) | 29 (49.2%) | 0.19 |
| Ethnicity | 0.79 | |||
| Chinese | 86 (69.9%) | 46 (71.8%) | 40 (67.8%) | |
| Malay | 26 (21.2%) | 12 (18.8%) | 14 (23.7%) | |
| Indian and others | 11 (8.9%) | 6 (9.4%) | 5 (8.5%) | |
| Barthel index | 15.5 | 15.5 | 15 | 0.71 |
| Interquartile range | (10.8, 20.0) | (11, 19.3) | (10.0, 20.0) | |
| Number of participants | 106 | 54 | 51 | |
| Vaccinations at baseline | ||||
| Influenza | 6 (4.9%) | 4 (6.3%) | 2 (3.4%) | 0.68 |
| Pneumococcal PPSV23 | 1 (0.8%) | 0 (0.0%) | 1 (1.7%) | 0.48 |
| Pneumococcal PCV13 | 7 (5.7%) | 4 (6.3%) | 3 (5.1%) | 1.00 |
| Grouped discharge diagnoses | ||||
| Falls related | 45 (36.6%) | 26 (40.6%) | 19 (32.2%) | |
| Cardiac | 17 (13.8%) | 7 (10.9%) | 10 (16.9%) | |
| Gastro-intestinal | 8 (6.5%) | 2 (3.1%) | 6 (10.2%) | |
| Infective episode | 13 (10.6%) | 6 (9.4%) | 7 (11.8) | |
| Musculoskeletal | 6 (4.9%) | 4 (6.2%) | 2 (3.4%) | |
| Neurological | 20 (16.3%) | 12 (18.7%) | 8 (13.6%) | |
| Respiratory | 1 (0.8%) | 1 (1.6%) | 0 (0%) | |
| Others | 13 (10.6%) | 6 (9.4%) | 7 (11.8%) | |
| Concomitant dementia | 7 (5.7%) | 6 (9.4%) | 1 (2%) |
PPSV23 23-valent pneumococcal polysaccharide vaccine, PCV13 13-valent pneumococcal conjugate vaccine
Fig. 3Proportion of participants with re-admissions to hospital for acute respiratory infections over time. Log-rank test comparing the prevention bundle to usual care shows a significant difference in mean time from randomization to next hospitalization due to acute respiratory infections (9.5 months vs. 11.5 months; P = 0.049). One year after randomization, the intervention group had a lower risk of hospitalization for acute respiratory infections (18.6% vs. 34.4%; P = 0.049)
Study outcomes from multi-component interventions
| Study outcomes | All | Usual care | Intervention | |
|---|---|---|---|---|
| Hospital length of stay | ||||
| Number of participants | 123 | 64 | 59 | |
| Median hospital LOS (days) | 8 | 8 | 8 | 0.86 |
| Interquartile range | (5–12) | (5–11) | (5–13) | |
| 30-day hospital re-admission | ||||
| Number of participants | 122 | 64 | 58 | |
| No | 88 (72.1%) | 46 (71.9%) | 42 (72.4%) | 0.95 |
| Yes | 34 (27.9%) | 18 (28.1%) | 16 (27.6%) | |
| 30-day respiratory re-admission | ||||
| Number of participants | 34 | 18 | 16 | 0.34 |
| No | 29 (85.3%) | 14 (77.8%) | 15 (93.8%) | |
| Yes | 5 (14.7%) | 4 (22.2%) | 1 (6.3%) | |
| Mortality overall | ||||
| No | 51 (79.7%) | 47 (79.7%) | 0.99 | |
| Yes | 13 (20.3%) | 12 (20.3%) | ||
| < 30 days of discharge | 2 (3.1%) | 5 (8.4%) | ||
| 30–90 days of discharge | 1 (1.6%) | 0 (0.0%) | ||
| 90 days–1 year of discharge | 10 (15.6%) | 7 (11.9%) | ||
| Cause of mortality | ||||
| Non-respiratory related | 6 (9.4%) | 9 (15.2%) | ||
| Respiratory infection | 7 (10.9%) | 3 (5.1%) | 0.34 |
Implementation of prevention bundle components
| Bundle component | All | Usual care | Intervention | |
|---|---|---|---|---|
| Number of participants | 123 | 64 | 59 | |
| Dysphagia | ||||
| Not screened | 50 (40.7%) | 49 (76.6%) | 1 (1.7%) | < 0.001 |
| Screened | 73 (59.3%) | 15 (23.4%) | 58 (98.3%) | |
| No dysphagia | 39 (31.7%) | 2 (3.1%) | 37 (62.7%) | |
| Present | 34 (27.6%) | 13 (20.3%) | 21 (35.6%) | |
| Cognitive dysphagia | 2 | 1 | 1 | |
| Mild dysphagia | 21 | 8 | 13 | |
| Mild-to-moderate | 6 | 2 | 4 | |
| Moderate | 1 | 0 | 1 | |
| Presbyphagia | 4 | 2 | 2 | |
| Oral hygiene | 53 (43.1%) | 0 (0.0%) | 53 (89.8%) | |
| Adherence to mouthwash | 23 (38.9%) | |||
| Bed tilt | 58 (47.2%) | 0 (0.0%) | 58 (98.3%) | |
| Vaccinations during study | ||||
| Influenza | 42 (34.1%) | 11 (17.2) | 32 (54.5%) | < 0.001 |
| Pneumococcal | ||||
| PPSV23 | 1 (0.8%) | 0 (0.0%) | 1 (1.7%) | 0.48 |
| PCV13 | 43 (35.0%) | 13 (20.3%) | 30 (50.8%) | < 0.001 |
PPSV23 23-valent pneumococcal polysaccharide vaccine, PCV13 13-valent pneumococcal conjugate vaccine